Compositions and methods for treating ovarian tumors
AssigneesDana-Farber Cancer Institute, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
InventorsLevi Garraway, Benjamin Izar, Aviv Regev, Orit Rozenblatt-Rosen, Asaf Rotem, Elizabeth Stover, Itay Tirosh
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.
Claims44
A method for treating or preventing a gynecological tumor in a subject comprising:
- identifying a subject with a gynecological tumor;
- and
- administering to the subject a therapeutically effective amount of a signal transducer and activator of transcription 3 (STAT3) activity inhibitor,
- thereby treating or preventing the gynecological tumor in the subject.
A method for treating a gynecological tumor in a subject comprising:
- identifying a subject with a gynecological tumor;
- administering to the subject a therapeutically effective amount of a chemotherapeutic agent to inhibit the gynecological tumor;
- and
- administering to the subject a therapeutically effective amount of a STAT3 activity inhibitor to prevent recurrence of the gynecological tumor and development of metastases, thereby treating or preventing the gynecological tumor in the subject.
A method for treating a platinum-resistant gynecological tumor in a subject comprising:
- identifying a subject with a platinum-resistant gynecological tumor;
- administering to the subject a therapeutically effective amount of a STAT3 activity inhibitor;
- administering to the subject a therapeutically effective amount of a chemotherapeutic agent, thereby treating the platinum-resistant gynecological tumor in the subject.
A method of treating platinum-based chemotherapy resistant ovarian cancer comprising treating a subject in need thereof with an inhibitor of the JAK/STAT pathway.
A method of treating ovarian cancer comprising treating a subject in need thereof with an agent capable of inhibiting expression or activity of one or more genes or polypeptides selected from the group consisting of JAK1, STAT3, STAT2, STAT1, OSMR, STAT6, RELA, ERBB2, GF1R, ERBB3, IL10RB, FGFR1, CXCR4, CXCL2, CXCL10, CXCL11, HLA-DRA, HLA-DRB1, HLA-DQB1, IDO1, MYBL2 and FGF13.
A method of predicting a response to platinum-based chemotherapy in a subject suffering from ovarian cancer comprising detecting in a tumor sample obtained from the subject expression of one or more genes selected from the group consisting of JAK1, STAT3, STAT2, STAT1, OSMR, STAT6, RELA, ERBB2, GF1R, ERBB3, IL10RB, FGFR1, CXCR4, CXCL2, CXCL10, CXCL11, HLA-DRA, HLA-DRB1, HLA-DQB1, IDO1, MYBL2 and FGF13, wherein high expression in the tumor sample indicates a weak response to platinum-based chemotherapy and low expression indicates a strong response to platinum-based chemotherapy.
A method of detecting ovarian cancer stem cells in a tumor sample obtained from a subject suffering from ovarian cancer comprising detecting expression of a gene signature comprising one or more genes selected from the group consisting of ALDH1A3, CD24, CD133, FN1, ACTA2, MYL9, GAS6, IGFBP5, FGFR1, CALD1, CFI, CRB2, PRDX4, IGFBP6 and RPS20.
A method of treating ovarian cancer comprising treating a subject in need thereof with an agent capable of targeting ovarian cancer stem cells characterized by a gene signature comprising one or more genes selected from the group consisting of ALDH1A3, CD24, CD133, FN1, ACTA2, MYL9, GAS6, IGFBP5, FGFR1, CALD1, CFI, CRB2, PRDX4, IGFBP6 and RPS20.
Dependencies are inferred from the claim text.